FDA’s Updated Drug Shortage List Loaded with Critical Medicines
The Food and Drug Administration recently updated its drug shortage list. More than half of the updates include drugs on the essential medicines list.
Senate Puts FDA Re-authorization Deal in Jeopardy Over Infant Formula Crisis
Senator Burr warned the FDA that until the Senate is okay with their response to the infant formula crisis, and present a plan to prevent it in the future, the Generic Drug User Fee Authorization bill might be put on hold.
CPA Urges President Biden to Address Decades of Failure by the FDA
WASHINGTON — The Coalition for a Prosperous America (CPA) urged President Joe Biden to address the decades of dereliction of duty by the Food and
CPA Letters to Leaders of House, Senate Health Care Committees Regarding FDA’s Failure on Essential Generic Medicines, Shortages
CPA sent the following letters to the Chairs and Ranking Members of the Senate Health, Education, Labor, and Pensions Committee and the House Energy and
CPA Letter to President Biden Regarding Essential Generic Medicines, Excessive Offshoring, and Failure of Safety and Efficacy
CPA sent the following letter to President Joe Biden requesting that his administration take action to address the failures of the Food and Drug Administration
Pharma and Trade Deals Top of Mind in China Commission Hearing
The U.S. China Economic and Security Review Commission discussed the tight-linked China-India pharmaceutical supply chain, and tossed aside the notion that sweeping trade deals with India and the region are good ideas.
FDA Funding Bill Heads to Final Committee, With One Major Stumbling Block
The Health subcommittee of the House Energy and Commerce Committee have moved the FDA user-fee reauthorization bill to final committee. Chairwoman Eshoo says it is on track for September approval.
CPA Launches Americans for Safe Drugs
Fighting Against Chinese & Indian Generic Pharmaceutical Manufacturers Exporting Unsafe Products to the U.S. WASHINGTON — The Coalition for a Prosperous America (CPA) today announced
House FDA Hearing: No Plan for Domestic Drug Manufacturing
A House committee hearing on the FDA focused on diversity in clinical trials, fast approval for cancer drugs, and no word on foreign vs domestic generic pharmaceutical labs.
Made in USA Pharma Supply Chain Amendment Passes Unanimously
Sen. Tina Smith’s bill to provide $500 million in grants for domestic pharmaceutical manufacturers passes with flying colors and will be part of PREVENT Pandemics Act.
